Rewriting the rules of immunoconjugate therapies.
Location: United States, Massachusetts, Cambridge
Phone: +1 617-498-0020
Total raised: $99M
Founded date: 2001
Investors 6
| Date | Name | Website |
| 06.07.2021 | New Enterp... | nea.com |
| - | Rho Ventur... | rhoventure... |
| - | F-Prime Ca... | fprimecapi... |
| - | Eight Road... | eightroads... |
| 30.10.2023 | SymBiosis | symbiosis.... |
| - | Bain Capit... | baincapita... |
Funding Rounds 4
| Date | Series | Amount | Investors |
| 16.06.2016 | Series C | $33M | - |
| 02.03.2015 | Series B | $35M | - |
| 31.07.2012 | Series A | $27M | - |
| 24.10.2008 | - | $4M | - |
Mentions in press and media 18
| Date | Title | Description | Source |
| 22.12.2022 | Mersana Therapeutics Announces Research Collaboration and Co... | Collaboration focuses on discovering novel STING-agonist ADCs for up to two targets leveraging Mersa... | einpresswi... |
| 08.04.2020 | Mersana Therapeutics Raises $65 Million | CAMBRIDGE, Mass., April 07, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (Nasdaq: MRSN), a cl... | citybizlis... |
| 18.04.2019 | When a new biotech’s drug pipeline is more of a ‘hypeline’... | The easiest way to peek inside the inner workings of a brand-new biotech company? Check out its pipe... | statnews.c... |
| 04.01.2019 | Deserted by Takeda, Mersana abandons lead drug | Mersana Therapeutics’ rocky road in developing its lead drug has culminated in the abando... | endpts.com... |
| 16.03.2018 | Longtime R&D chief Bischofberger leaves Gilead; Nova... | Norbert Bischofberger → After a stretch of close to 30 years at Gilead $GILD, longtime R&D... | endpts.com... |
| 28.06.2017 | Term Sheet — Wednesday, June 28 | Et Cetera Good morning! Some quick notes today… Paid Content What you need to know about growing c... | fortune.co... |
| 02.06.2017 | Term Sheet — Friday, June 2 | NEW MONEY, FOOD IPO Spin-outs: Last week we reported on the trend of junior partners at venture fir... | fortune.co... |
| 16.06.2016 | Biotech Company Mersana Therapeutics Closes $33M Series C Fi... | Mersana Therapeutics, Inc., a Cambridge, MA-based biotechnology company focused on discovering and d... | finsmes.co... |
| 16.06.2016 | Mersana Therapeutics Raises $33M Series C Led by Wellington ... | CAMBRIDGE, Mass., June 16, 2016 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc., a biotechnology comp... | citybizlis... |
| 02.03.2015 | Mersana Raises $35M in Series B | CAMBRIDGE, MA, Mersana Therapeutics, Inc., announced today that it raised $35 million in Series B-... | vcnewsdail... |
Show more